Results 111 to 120 of about 15,674 (165)

HIF1 inhibition targets tumoral and myeloid cells, and is a promising therapy for metastatic castration-resistant prostate cancer. [PDF]

Cell Death Dis
Yanushko D, Pichot A, Vincent A, Keime C, Laverny G, Metzger D.   +5 more
europepmc   +1 more source

Identification of genetically predicted protein biomarkers and drug targets for prostate cancer via Mendelian randomization

VIEW, Volume 7, Issue 3, June 2026.
Prostate cancer, a leading cause of cancer in men globally, urgently requires improved diagnostic and treatment strategies. This study analyzed large genetic datasets and identified five key proteins (THBD, DST, IFI27L2, OSBPL10, PPP1R14A) that either increase or decrease cancer risk, while also exploring their roles in immune response and potential ...
Maoping Cai, Tianming Peng, Zhiyue Xie, Chuqian Zhen, Chen Yao, Nan Peng, Qianyi Li, Yuzhong Yu, Jiming Bao, Xian‐Lu Song, Mingkun Chen, Shan‐Chao Zhao   +11 more
wiley   +1 more source

Testosterone Replacement in Prostate Carcinoma: A Systematic Review of an Emerging Paradigm and Therapeutic Potential. [PDF]

Cureus
Robinson J, Banerjee I, Banerjee I.
europepmc   +1 more source

Synergistic RU486 and olaparib therapy enhances apoptosis in endometriosis by simultaneously targeting hormonal signalling and DNA repair

British Journal of Pharmacology, Volume 183, Issue 11, Page 2947-2968, June 2026.
Background and Purpose Endometriosis is a chronic, hormone‐dependent disorder characterized by ectopic implantation of endometrial tissue, often accompanied by pain and infertility. Although the progesterone receptor modulator RU486 is effective for pain relief, its impact on lesion regression is limited, possibly due to apoptosis resistance and ...
Yujie Peng, Meng Zhang, Libo Zhu, Wenqiang Qian, Jingjing Yan, Huidi Jiang, Yu Xin, Ying Zhang, Dongli Sun, Weidong Fei, Mengdan Zhao   +10 more
wiley   +1 more source

Mapping prostate cancer pathobiology: A review of genetically engineered mouse models (GEMMs). [PDF]

Gene
Pederzoli F, Pakula H, Rodrigues S, Garner R, Nuzzo PV, Bleve S, Rickman DS, Fanelli GN, Loda M.   +8 more
europepmc   +1 more source

Survival after spinal surgery for metastases in men with castration-sensitive vs castration-resistant prostate cancer: a nationwide register-based study. [PDF]

Sci Rep
Wänman J, Farhang M, Nyström H, Styrke J, Häggström C, Stattin P, Crnalic S.   +6 more
europepmc   +1 more source

IL-6/STAT3 signaling in prostate cancer: CAF-driven immune evasion and therapeutic opportunities. [PDF]

Front Immunol
Zhou T, Li Y, Liu Z, Zeng Z, Li T, Chen L, Zhao H, Wu X, Shen Y, Fan H, Zhu X, Zhou Y, Zou L, Zhao D.   +13 more
europepmc   +1 more source

Quantitative PSMA PET Biomarkers for Predicting Response to ¹⁷⁷Lu-PSMA Therapy in Prostate Cancer: A Systematic Review and Meta-analysis. [PDF]

J Nucl Med
Kiani I, Siri MA, Babaei M, Aliasghari MM, Mohammadzadeh S, Mohammadi S, Salavati A.   +6 more
europepmc   +1 more source

Paradoxical Effect of Obesity on Survival Outcomes in Prostate Cancer Patients Receiving Enzalutamide and Abiraterone. [PDF]

Medicina (Kaunas)
Kaya BE, Koçak MZ, Yıldız O, Aykut T, Gürbüz AF, Genç Ö, Karakurt Eryılmaz M, Araz M, Artaç M.   +8 more
europepmc   +1 more source

Prognostic Value of Cycle 1 SPECT SUV_mean in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with ¹⁷⁷Lu-PSMA-617. [PDF]

J Nucl Med
Ghodsi A, Demirci RA, Gulati R, Nelson PS, Raychaudhuri R, Cheng HH, Sunkara R, Khan H, Rios RN, Hsieh A, Grivas P, Montgomery B, Yezefski TA, Yu EY, Schweizer MT, Chen DL, Iravani A.   +16 more
europepmc   +1 more source